Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis

Journal of the Pancreas

Volumn 12, Issue 4, 2011, Pages 377-383

  Buxbaum, James L ^a   Biggins, Scott W ^b   Bagatelos, Karen C ^c   Inadomi, John M ^d   Ostroff, James W ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cholangitis; Cholestasis Extrahepatic; Pancreatic neoplasms; Stents

Indexed keywords

CAPECITABINE; CISPLATIN; GEMCITABINE;

ADULT; AGED; ARTICLE; BARE METAL STENT; BILE DUCT OBSTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHOLANGITIS; CONTROLLED STUDY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; INOPERABLE CANCER; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREATITIS; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME; TUMOR VOLUME; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHOLANGITIS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 79960220893     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hochster HS, Haller DG, de Gramont A, et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006; 107:676-85. [PMID 16847885]
2. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [PMID 9196156]
3. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6. [PMID 17452677]
4. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21:3402-8. [PMID 12885837]
5. Ko AH, Quivey JM, Venook AP, et al. A phase II study of fixeddose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007; 68:809-16. [PMID 17363191]
6. Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev 2006:CD004200. [PMID 16625598]
7. Speer AG, Cotton PB, Russell RC, et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2:57-62. [PMID 2439854]
8. Smith AC, Dowsett JF, Russell RC, et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344:1655-60 [PMID 7996958]
9. Artifon EL, Sakai P, Cunha JE, et al. Surgery or endoscopy for palliation of biliary obstruction due to metastatic pancreatic cancer. Am J Gastroenterol 2006; 101:2031-7. [PMID 16968509]
10. Prat F, Chapat O, Ducot B, et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998; 47:1-7. [PMID 9468416]
11. Davids PH, Groen AK, Rauws EA, et al. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992; 340:1488-92. [PMID 1281903]
12. Carr-Locke DL, Ball, TJ, Connors, PJ, et al. Multicenter, randomized trial of wallstent biliary endoprosthesis versus plastic stent. Gastrointest Endosc 1993; 3 9:310.
13. Knyrim K, Wagner HJ, Pausch J, et al. A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. Endoscopy 1993; 25:207-12. [PMID 8519239]
14. Kaassis M, Boyer J, Dumas R, et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc 2003; 57:178-82. [PMID 12556780]
15. Prat F, Chapat O, Ducot B, et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut 1998; 42:76-80. [PMID 9505889]
16. Lee JG. Diagnosis and management of acute cholangitis. Nat Rev Gastroenterol Hepatol 2009; 6:533-541. [PMID 21207254]
17. Isayama H, Komatsu Y, Tsujino T, et al. A prospective randomised study of covered versus ''uncovered'' diamond stents for the management of distal malignant biliary obstruction. Gut 2004; 53:729-34. [PMID 15082593]
18. Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc 2006; 63:986-95. [PMID 16733114]
19. O'Brien S, Hatfield AR, Craig PI, et al. A three year follow up of self expanding metal stents in the endoscopic palliation of longterm survivors with malignant biliary obstruction. Gut 1995; 36:618-21. [PMID 7537708]
20. Yoon WJ, Lee JK, Lee KH, et al. A comparison of covered and uncovered Wallstents for the management of distal malignant biliary obstruction. Gastrointest Endosc 2006; 63:996-1000. [PMID 16733115]
21. Takasawa O, Fujita N, Kobayashi G, et al. Endoscopic biliary drainage for patients with unresectable pancreatic cancer with obstructive jaundice who are to undergo gemcitabine chemotherapy. World J Gastroenterol 2006; 12:7299-303. [PMID 17143944]
22. Maire F, Hammel P, Ponsot P, et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol 2006; 101:735-42. [PMID 16635221]
23. Levy P HP, O'Toole D, Tigaud J, et al. Survival of patients with non-resectable pancreatic ductal adenocarcinoma: published data is rendered obsolete with new therapeutic strategies. Gastroenterology 2002; 122:A-567.
24. Saif MW. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. JOP 2007; 8:365-73. [PMID 17625289]
25. Tham TC, Carr-Locke DL, Vandervoort J, et al. Management of occluded biliary Wallstents. Gut 1998; 42:703-7. [PMID 9659168]
26. Bueno JT, Gerdes H, Kurtz RC. Endoscopic management of occluded biliary Wallstents: a cancer center experience. Gastrointest Endosc 2003; 58:879-84. [PMID 14652557]
27. Familiari P, Bulajic M, Mutignani M, et al. Endoscopic removal of malfunctioning biliary self-expandable metallic stents. Gastrointest Endosc 2005; 62:903-10. [PMID 16301035] Neoplasms; Stents
28. Speer AG, Cotton PB, Rode J, et al. Biliary stent blockage with bacterial biofilm. A light and electron microscopy study. Ann Intern Med 1988; 108:546-53. [PMID 2450501]
29. Valiozis I, Zekry A, Williams SJ, et al. Palliation of hilar biliary obstruction from colorectal metastases by endoscopic stent insertion. Gastrointest Endosc 2000; 51:412-7. [PMID 10744811]
30. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476-87. [PMID 15689586]
31. Odemis B, Parlak E, Basar O, et al. Biliary tract obstruction secondary to malignant lymphoma: experience at a referral center. Dig Dis Sci 2007; 52:2323-32. [PMID 17406815]
32. Farrell J, Elsaleh H, Garcia, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136:187-195. [PMID 18992248]
33. Leung J, Rahim N. The role of covered self-expandable metallic stents in malignant biliary strictures. Gastrointest Endosc 2006; 63:1001-3. [PMID 16733116]